Cargando…
Design and Synthesis of a New Soluble Natural β-Carboline Derivative for Preclinical Study by Intravenous Injection
Harmine is a natural β-carboline compound showing several biological activities, including antiproliferative properties, but this soluble natural molecule lacks selectivity. Harmine derivatives were reported to overcome this problem, but they are usually poorly soluble. Here, we designed and synthes...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471559/ https://www.ncbi.nlm.nih.gov/pubmed/30934601 http://dx.doi.org/10.3390/ijms20061491 |
_version_ | 1783412055559110656 |
---|---|
author | Marx, Sébastien Bodart, Laurie Tumanov, Nikolay Wouters, Johan |
author_facet | Marx, Sébastien Bodart, Laurie Tumanov, Nikolay Wouters, Johan |
author_sort | Marx, Sébastien |
collection | PubMed |
description | Harmine is a natural β-carboline compound showing several biological activities, including antiproliferative properties, but this soluble natural molecule lacks selectivity. Harmine derivatives were reported to overcome this problem, but they are usually poorly soluble. Here, we designed and synthesized a new 2, 7, 9-trisubstituted molecule (1-methyl-7-(3-methylbutoxy)-9-propyl-2-[(pyridin-2-yl)methyl]-9H-pyrido[3,4-b]indol-2-ium bromide) with a solubility of 1.87 ± 0.07 mg/mL in a simulated injection vehicle. This compound is stable for at least 72 h in acidic and physiological conditions (pH 1.1 and 7.4) as well as in a simulated injection vehicle (physiological liquid + 0.1% Tween80®). Solubility in those media is 1.06 ± 0.08 mg/mL and 1.62 ± 0.13 mg/mL at pH 7.4 and 1. The synthesized molecule displays a significant activity on five different cancer cell lines (IC(50) range from 0.2 to 2 µM on A549, MDA-MB-231, PANC-1, T98G and Hs683 cell lines). This compound is also more active on cancer cells (MDA-MB-231) than on normal cells (MCF-10a) at IC(50) concentrations. Due to its high activity at low concentration, such solubility values should be sufficient for further in vivo antitumoral activity evaluation via intravenous injection. |
format | Online Article Text |
id | pubmed-6471559 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64715592019-04-26 Design and Synthesis of a New Soluble Natural β-Carboline Derivative for Preclinical Study by Intravenous Injection Marx, Sébastien Bodart, Laurie Tumanov, Nikolay Wouters, Johan Int J Mol Sci Article Harmine is a natural β-carboline compound showing several biological activities, including antiproliferative properties, but this soluble natural molecule lacks selectivity. Harmine derivatives were reported to overcome this problem, but they are usually poorly soluble. Here, we designed and synthesized a new 2, 7, 9-trisubstituted molecule (1-methyl-7-(3-methylbutoxy)-9-propyl-2-[(pyridin-2-yl)methyl]-9H-pyrido[3,4-b]indol-2-ium bromide) with a solubility of 1.87 ± 0.07 mg/mL in a simulated injection vehicle. This compound is stable for at least 72 h in acidic and physiological conditions (pH 1.1 and 7.4) as well as in a simulated injection vehicle (physiological liquid + 0.1% Tween80®). Solubility in those media is 1.06 ± 0.08 mg/mL and 1.62 ± 0.13 mg/mL at pH 7.4 and 1. The synthesized molecule displays a significant activity on five different cancer cell lines (IC(50) range from 0.2 to 2 µM on A549, MDA-MB-231, PANC-1, T98G and Hs683 cell lines). This compound is also more active on cancer cells (MDA-MB-231) than on normal cells (MCF-10a) at IC(50) concentrations. Due to its high activity at low concentration, such solubility values should be sufficient for further in vivo antitumoral activity evaluation via intravenous injection. MDPI 2019-03-25 /pmc/articles/PMC6471559/ /pubmed/30934601 http://dx.doi.org/10.3390/ijms20061491 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Marx, Sébastien Bodart, Laurie Tumanov, Nikolay Wouters, Johan Design and Synthesis of a New Soluble Natural β-Carboline Derivative for Preclinical Study by Intravenous Injection |
title | Design and Synthesis of a New Soluble Natural β-Carboline Derivative for Preclinical Study by Intravenous Injection |
title_full | Design and Synthesis of a New Soluble Natural β-Carboline Derivative for Preclinical Study by Intravenous Injection |
title_fullStr | Design and Synthesis of a New Soluble Natural β-Carboline Derivative for Preclinical Study by Intravenous Injection |
title_full_unstemmed | Design and Synthesis of a New Soluble Natural β-Carboline Derivative for Preclinical Study by Intravenous Injection |
title_short | Design and Synthesis of a New Soluble Natural β-Carboline Derivative for Preclinical Study by Intravenous Injection |
title_sort | design and synthesis of a new soluble natural β-carboline derivative for preclinical study by intravenous injection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471559/ https://www.ncbi.nlm.nih.gov/pubmed/30934601 http://dx.doi.org/10.3390/ijms20061491 |
work_keys_str_mv | AT marxsebastien designandsynthesisofanewsolublenaturalbcarbolinederivativeforpreclinicalstudybyintravenousinjection AT bodartlaurie designandsynthesisofanewsolublenaturalbcarbolinederivativeforpreclinicalstudybyintravenousinjection AT tumanovnikolay designandsynthesisofanewsolublenaturalbcarbolinederivativeforpreclinicalstudybyintravenousinjection AT woutersjohan designandsynthesisofanewsolublenaturalbcarbolinederivativeforpreclinicalstudybyintravenousinjection |